FY2024 Earnings Estimate for uniQure Issued By HC Wainwright

uniQure (NASDAQ:QURE) – Research analysts at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for uniQure in a note issued to investors on Wednesday, November 6th. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will post earnings of ($4.16) per share for the year, up from their previous forecast of ($4.84). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for uniQure’s current full-year earnings is ($4.10) per share. HC Wainwright also issued estimates for uniQure’s Q4 2024 earnings at ($0.74) EPS, Q1 2025 earnings at ($0.62) EPS, Q2 2025 earnings at ($0.64) EPS, Q3 2025 earnings at ($0.66) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($2.69) EPS, FY2026 earnings at ($2.50) EPS, FY2027 earnings at ($1.20) EPS and FY2028 earnings at $1.40 EPS.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The firm had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%.

Other research analysts also recently issued research reports about the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $28.00 price objective on shares of uniQure in a research note on Wednesday. Royal Bank of Canada reduced their price target on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Wednesday. The Goldman Sachs Group dropped their price target on uniQure from $10.00 to $9.00 and set a “neutral” rating for the company in a research note on Wednesday. StockNews.com upgraded uniQure to a “sell” rating in a research report on Thursday, October 17th. Finally, Raymond James restated an “outperform” rating and set a $20.00 target price on shares of uniQure in a research report on Thursday, October 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, uniQure presently has a consensus rating of “Hold” and a consensus target price of $17.00.

uniQure Stock Performance

QURE opened at $7.79 on Friday. The company’s 50 day moving average is $5.77 and its 200 day moving average is $5.82. The company has a market cap of $379.68 million, a price-to-earnings ratio of -1.57 and a beta of 0.90. uniQure has a 12-month low of $3.73 and a 12-month high of $11.35. The company has a current ratio of 6.51, a quick ratio of 7.36 and a debt-to-equity ratio of 0.92.

Institutional Investors Weigh In On uniQure

A number of institutional investors and hedge funds have recently bought and sold shares of QURE. Vanguard Personalized Indexing Management LLC increased its position in uniQure by 21.0% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 2,306 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in shares of uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 3,663 shares in the last quarter. American Century Companies Inc. increased its position in shares of uniQure by 14.6% during the second quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock worth $303,000 after purchasing an additional 8,642 shares in the last quarter. Atria Investments Inc acquired a new position in uniQure during the 3rd quarter valued at about $53,000. Finally, Clear Harbor Asset Management LLC raised its position in shares of uniQure by 35.2% in the 2nd quarter. Clear Harbor Asset Management LLC now owns 48,000 shares of the biotechnology company’s stock valued at $215,000 after purchasing an additional 12,500 shares during the last quarter. 78.83% of the stock is owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.